TITLE

Naftidrofuryl in Chronic Arterial Disease. Results of a Controlled Multicenter Study

AUTHOR(S)
Trubestein, G.; .Bohme, H; Heidrich, H.; Heinrich, F.; Hirche, H.; Maass, U.; Mori, H.; Rudofsky, G.
PUB. DATE
November 1984
SOURCE
Angiology;Nov1984, Vol. 35 Issue 11, p701
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In a double blind, randomized multicenter study naftidrofuryl, a vasoactive substance, was compared with placebo in the treatment of 104 patients with chronic arterial occlusive disease. After a run-in period of four weeks the patients received either naftidrofuryl (600mg daily) or placebo over 12 weeks. The pain-free and the total walking distances improved significantly in both groups. However, the difference in the improvement of the pain-free walking distance was significant (p < 0.02) in favour of naftidrofuryl. There also was a difference in the improvement of the total walking distance in favour of naftidrofuryl which was not significant. The results indicate that naftidrofuryl has a beneficial effect on the symp- toms and lengthens the painfree walking distance in patients with arterial occlusive disease.
ACCESSION #
16352893

 

Related Articles

  • Therapeutic Effect of Ticlopidine, a New Inhibitor of Platelet Aggregation, on Chronic Arterial Occlusive Diseases, a Double-blind Study versus Placebo. Katsumura, Tatsuki; Mishima, Yoshio; Kamiya, Kisaku; Sakaguchi, Shukichi; Tanabe, Tatsuzo; Sakuma, Akira // Angiology;Jun1982, Vol. 33 Issue 6, p357 

    The clinical efficacy of ticlopidine, a platelet aggregation inhibitor, was evaluated in a double-blind placebo-controlled study on 193 patients with ischemic ulcers due to chronic arterial occlusion. In the group treated with ticlopidine, significantly better efficacy was noted over the placebo...

  • Influence of venous emptying on the reactive hyperemic blood flow response. Bahadir, Zeki; Tisdell, Eric; Arce Esquivel, Arturo A.; Dobrosielski, Devon A.; Welsch, Michael A. // Dynamic Medicine;2007, Vol. 6, p3 

    Background: Previous research indicates that venous emptying serves as a stimulus for vasodilation in the human forearm. This suggests the importance of recognizing the potential influence of venous volume on reactive hyperemic blood flow (RHBF) following occlusion. The purpose of this study was...

  • UNINHIBITED REVERSIBLE ANTIDROMIC VASODILATION IN PATHOPHYSIOLOGIC DISEASES: ARTERIOSCLEROSIS, CARCINOGENESIS, NEURITIS, AND OSTEOPOROSIS. Hackett, George S. // Angiology;Feb1966, Vol. 17 Issue 2, p109 

    The basic heritable physiologic mechanism of man and other vertebrates consists of neurovascular stimulus response activities in which afferent impulse potential is redirected in the terminal neuron, by presynaptic axon reflex for uninhibited antidromic conduction, to within the walls of...

  • PERITRATE IN PERIPHERAL ARTERIAL DISEASES. Samuels, Saul S.; Padernacht, Elias D. // Angiology;Feb1952, Vol. 3 Issue 1, p20 

    Clinical study of 30 cases of arteriosclerosis obliterans treated with Peritrate showed improvement in symptoms of intermittent claudication in 20 cases. Final determination of the value of this, as well as all other vasodilators, must await extensive objective studies of a large series of cases...

  • VASODILATING DRUGS. Samuels, Saul S. // Angiology;Feb1953, Vol. 4 Issue 1, p101 

    Comments on the use of vasodilating drugs in the treatment of peripheral arterial diseases. Regard of vasolidating drugs as valuable adjuncts in the treatment of arterial insufficiency of the extremities; Reminders when testing the value of vasodilating drugs from the clinical standpoint; Danger...

  • Buflomedil in Arterial Occlusive Disease: Results of a Controlled Multicenter Study. Trubestein, G.; Balzer, K.; Bisler, H.; Kluken, N.; Muller-Wiefel, H.; Unkel, B.; Mahfoud, Y.; Ziegler, W. // Angiology;Aug1984, Vol. 35 Issue 8, p500 

    In a double-blind, randomised multicentre study buflomedii, a vasoactive substance, was compared with placebo in the treatment of 93 patients with chronic arterial occlusive disease. After a run-in period of four weeks the patients received either buflomedil (600 mg daily) or placebo over 12...

  • RANDOMISED CONTROLLED TRIAL TO ASSESS THE VASCULAR AND BIOCHEMICAL EFFECTS OF CILOSTAZOL IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE. O'Donnell, M. E.; Badger, S. A.; Sharif, M. A.; Makar, R. R.; Young, I. S.; Lau, L. L.; Lee, B.; Hannon, R. J.; Soong, C. V. // Ulster Medical Journal;2009, Vol. 78 Issue 1, p60 

    Objectives: Cilostazol improves walking distance. The study aimed to assess vascular and biochemical effects of cilostazol in peripheral arterial disease (PAD) patients. Methods: Patients were randomised in a double-blinded, placebo-controlled trial. Baseline clinical data were recorded...

  • A Primary Care Approach to the Patient with Claudication. Carman, Teresa L.; Fernandez Jr., Bernardo B. // American Family Physician;2/15/2000, Vol. 61 Issue 4, p1027 

    Deals with the primary care approach to a patient with peripheral arterial occlusive disease (PAOD) in the United States. History and occurrence of PAOD; Symptoms of PAOD; Clinical management of PAOD.

  • Peripheral Arterial Disease: Why It Happens and What to Do.  // American Family Physician;2/15/2000, Vol. 61 Issue 4, p1034 

    Provides information on peripheral arterial disease (PAD). How arterial disease differs from PAD; How circulation is affected; Treatment of PAD.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics